Current Collaborators

Open to recruitment
  • Treatment Arm I: Odronextamab (Bispecific antibody), Regeneron Pharmaceuticals Inc.
  • Treatment Arm II: Loncastuximab tesirine (Antibody Drug Conjugate) with standard chemotherapy, ADC Therapeutics SA